- Company
- AbbVie Skyrizi approved, a new option for psoriasis
- by Eo, Yun-Ho Dec 9, 2019 06:26am
- Patients with plaque psoriasis now has another interleukin inhibitor option. On Dec. 3, AbbVie Korea announced Korean Ministry of Food and Drug Safety (MFDS) approved its interleukin-23 (IL-23) inhibitor Skyrizi Prefilled Syringe (risankizumab) for the treatment of moderate to severe psoriasis in adult patients who are candidates for sy
- Company
- 'Jardiance' reaffirms CV benefits over DPP-4 inhibitors
- by Eo, Yun-Ho Dec 9, 2019 06:26am
- Research shows that SGLT-2 inhibitor ‘Jardiance’ has more cardiovascular benefits than DPP-4 inhibitors. Boehringer Ingelheim and Lilly are the first to analyze Jardiance’s effectiveness of the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Asia study at the International Diabetes Federation, IDF presented at the General
- Company
- Celltrion, achieved first $1 billion exports in Korea
- by Chon, Seung-Hyun Dec 9, 2019 06:26am
- Celltrion Healthcare announced on the 5th that it won '$1 Billion Export Tower award ' at the 56th Trade Day Ceremony hosted by the Korea International Trade Association. Celltrion Healthcare is the first Korean pharmaceutical bio company to surpass $1 billion in annual exports. Only five companies have received more than $1 billion towers.
- Company
- Terramycin out again, Pfizer says February next year
- by Jung, Hye-Jin Dec 9, 2019 06:26am
- Pfizer Korea’s Terramycin ophthalmic ointment (3.5 g) is out of stock yet again. Pharmacies are expecting to fall into confusion as the versatile ointment is used vastly with affordable reimbursed price for various conditions. Pfizer Korea notified distributors and pharmacies recently that the production schedule of Terramycin ophthalmic
- Company
- Xolair reimbursed in China, Concerns over Korea Passing
- by Kim, Jin-Gu Dec 6, 2019 09:46am
- Novartis' Xolair is listed as a reimbursed drug in China. Analysts say that 'Korea Passing' is a reality in the industry Xolair, a chronic rash treatment drug, has been cited as one of the leading examples of Korea Passing, 'withholding or withdrawal of reimbursement in Korea to be listed in China and other countries'. China's Nation
- Company
- High-risk osteoporosis should increase bone formation first
- by Eo, Yun-Ho Dec 6, 2019 09:43am
- “For a high-risk patient, it would be better to use effective bone-forming agent from the beginning.” Amgen Korea held a press conference held on Dec. 4 for the launch of Evenity (romosozumab-aqqg), where Chair Chung Ho-yeon of Korean Society for Bone and Mineral Research (KSBMR) stressed on the importance of top-down style prescription
- Company
- 3rd PARP inhibitor Talzenna readies for Korean market
- by Eo, Yun-Ho Dec 6, 2019 09:39am
- A pharmaceutical industry source reported on Dec. 6 that Pfizer Korea has recently submitted an application to Ministry of Food and Drug Safety (MFDS) for an approval on PARP inhibitor Talzenna (talazoparib). When it gets the green light from the ministry, it would be the third PARP inhibitor medicine in Korea to enter the market, followi
- Company
- Ildong exclusively sells 9 kinds of GSK generic drugs
- by Chon, Seung-Hyun Dec 4, 2019 06:41am
- Ildong Pharmaceuticals announced on the 2nd that it has signed 9 co-promotional contracts with GlaxoSmithKline Consumer Healthcare Korea, including general medicines. With this agreement, Ildong Pharmaceuticals is a comprehensive cold medicine ‘ theraflu’, an ophthalmic drug ‘Otrivin’, a non-smoking supplement ‘Nicotinell’, a hyperhidr
- Company
- Narcolepsy treatment, Nuvigil settled down in Big 5 hospital
- by Eo, Yun-Ho Dec 4, 2019 06:41am
- Narcolepsy treatment, Nuvigil are facing the entry in Big 5 hospitals. According to the industry, Handokteva's Nuvigil (Amordafinil) has passed the SNUH, Severance Hospital, SMC, and ASAN Medical Center's drug commitee (DC). In addition, prescription code was generated at St. Vincent's Hospital of Catholic University. The system of St.
- Company
- Vyndaqel quick to request for ATTR-CM indication
- by Eo, Yun-Ho Dec 3, 2019 08:14pm
- In Korea, a rare disease treatment, Vyndaqel is applying for an expanded use in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In September, Pfizer Korea submitted an application to Ministry of Food and Drug Safety (MFDS) for approval on expanded indication for Vyndaqel, currently approved for treating hereditary transthy
